APP and Alzheimer disease: In the mouse model of Alzheimer’s disease (AD), the double transgenic mouse model APP/PS-1, the treatment of 7-month-old but not 12-month-old mice with ANDRO for one month significantly decreased the Amyloid-β (Aβ) aggregates.